Article: Biogen Idec Authorizes $3B Stock Buy-Back.

Staff Writer

After authorizing a $20 million share repurchase last October, Biogen Idec Inc.'s board of directors approved a second stock buy-back plan, this time for a whopping $3 billion.

Biogen Idec certainly has the money for such a deal. The Cambridge, Mass.-based company reported about $2.5 billion in cash, equivalents and securities as of March 31 and generated $716 million in first quarter revenues. Yet the repurchase will be funded half through cash and half through debt, ensuring that Biogen Idec remains capable of pursuing "small to moderate-sized acquisitions," according to Jose Juves, director of public affairs.

Earlier this year, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!